A major contributor to this article appears to have a
close connection with its subject. (December 2021) |
Monoclonal antibody | |
---|---|
Type | ? |
Clinical data | |
Other names | Anti-PD-1 monoclonal antibody IBI308 [1] |
Identifiers | |
CAS Number | |
UNII | |
KEGG |
Sintilimab, sold under the brand Tyvyt among others, is a medication used to treat Hodgkin's disease, [2] and has been approved in China. [3]
It is a fully human IgG4 monoclonal antibody [4] that binds to programmed cell death protein 1. [5]
It was jointly developed by Innovent Biologics [6] and Eli Lilly. [7]
Sintilimab is medication that is indicated for the treatment of relapsed or refractory classical Hodgkin's lymphoma [8] after failure of at least second-line systemic chemotherapy. [5]
Common side effects include fever, thyroid dysfunction, elevation of liver enzymes, and lung inflammation. [9]
Currently, more than 20 clinical trials are ongoing to evaluate the anti-tumor effect of sintilimab injection, either as monotherapy or in combination with other agents, on a variety of solid tumors. [10] In January 2019, the result of the registration trial of sintilimab in people with refractory or relapsed classical Hodgkin's lymphoma was published. [8]
A major contributor to this article appears to have a
close connection with its subject. (December 2021) |
Monoclonal antibody | |
---|---|
Type | ? |
Clinical data | |
Other names | Anti-PD-1 monoclonal antibody IBI308 [1] |
Identifiers | |
CAS Number | |
UNII | |
KEGG |
Sintilimab, sold under the brand Tyvyt among others, is a medication used to treat Hodgkin's disease, [2] and has been approved in China. [3]
It is a fully human IgG4 monoclonal antibody [4] that binds to programmed cell death protein 1. [5]
It was jointly developed by Innovent Biologics [6] and Eli Lilly. [7]
Sintilimab is medication that is indicated for the treatment of relapsed or refractory classical Hodgkin's lymphoma [8] after failure of at least second-line systemic chemotherapy. [5]
Common side effects include fever, thyroid dysfunction, elevation of liver enzymes, and lung inflammation. [9]
Currently, more than 20 clinical trials are ongoing to evaluate the anti-tumor effect of sintilimab injection, either as monotherapy or in combination with other agents, on a variety of solid tumors. [10] In January 2019, the result of the registration trial of sintilimab in people with refractory or relapsed classical Hodgkin's lymphoma was published. [8]